Connect with us

Hi, what are you looking for?

Tuesday, Dec 5, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

Cannabics Pharmaceuticals developing cannabinoid colon cancer treatment

The non-psychoactive formulation completed its preclinical trial Monday

Cannabics Pharmaceuticals files patent for using weed to fight colon cancer

A new cannabinoid-based treatment for colon cancer has passed a key testing phase.

On Monday, cannabis-derived drug developer Cannabics Pharmaceuticals, Inc. (OTCQX: CNBX) said the the new formulation completed its preclinical trial at a research facility in Israel.

The medicine contains a high dose of the the cannabinoid cannabidivarin (CBDV) and cannabigerolic acid (CBGA), which Cannabics said in a statement has anti-tumour properties.

The two cannabinoids have no psychoactive effect, unlike THC, so patients can take high doses of the medication without getting high, the company said.

Cannabics is an American company developing personalized cannabis-based cancer therapies at its research and development facility in Tel Aviv, Israel. The company is licensed by the Israeli Ministry of Health to do scientific and clinical research on cannabinoid formulations and cancer.

It’s widely established that cannabis can help treat nausea, pain and loss of appetite in cancer patients, but the idea that weed can actually fight cancer cells itself is still gaining traction in mainstream medicine.

Statements like “Cannabis can cure cancer” can be problematic because only certain cannabinoids have been clinically verified to have anti-tumour properties against certain cancers. Research has also shown that when people seek out alternative cancer therapies they often delay conventional treatments, which can reduce their ability to fight the disease in the long-run.

With cannabis legalization in Canada came a surge of research and funding for the medical applications of weed.

Read more: Cannabis is the overdose prevention tool we don’t use: symposium 

Now weed, and its many cannabinoids, is being tested in clinical trials for the treatment of a wide range of conditions, including post traumatic stress disorder, opioid addiction and cancer.

Cannabics is also testing how the cannabinoids cannabichromene (CBC) and cannabigerol (CBG) can be used to fight gastrointestinal cancer.

Read more: Cannabics Pharmaceuticals discovers 2 new cannabinoids that fight gastrointestinal cancer 

Top image via Cannabics Pharmaceuticals


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Flavours will include mint, peach ginger, lavender and chamomile


The cannabis candy is the first to feature a 3:1 ratio of CBC to THC


The resealable cans will become available in four flavours this month and are intended for multiple servings


The company claims its herbal blend product will revolutionize how cannabis is enjoyed around the globe